Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial

Daru

Volumn 16, Issue SUPPL. 1, 2008, Pages 41-48

  Bahrami, A ^a   Kamali, K ^b   Ali Asgharzadeh, A ^a   Hosseini, P ^c   Heshmat, R ^b,c   Khorram Khorshid, H R ^d   Gharibdoust, F ^b   Madani, S H ^e   Larijani, B ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^e Rabe Rashidi Institute Iran   (Iran)

Author keywords

ANGIPARS ; Diabetic foot; Oral; Topical; Ulcer

Indexed keywords

ANGIPARS; HERBACEOUS AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DIABETIC FOOT; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIZATION; FEMALE; FOLLOW UP; GRANULATION TISSUE; HUMAN; LABORATORY TEST; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; WOUND ASSESSMENT; WOUND CARE; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING; WOUND IRRIGATION;

EID: 38949152327     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Dinh TL, Veves AA. Review of the mechanisms implicated in the pathogenesis of the diabetic foot. Low Extrem Wounds 2005; 4:154-9.
2. Williams R, Van Gaal L, Lucioni C, Advisory board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45:S13-7.
3. Reiber GE. The epidemiology of diabetic foot problems. Diabetic Med 1998;13:S6-11.
4. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157-62.
5. Centers for Disease Control and Prevention. Diabetes - a serious public health problem. Atlanta: U.S. Department of Health and Human Services, 1998:1-5.
6. Humphrey CC, Palumbo PJ, Butters MA et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 1994;154:885-92.
7. Frykberg RG. A summary of guidelines for managing the diabetic foot. Adv Skin Wound Care 2005;18:209-14.
8. Frykberg RG. An evidence based approach to diabetic foot infections. Am J Surg 2003;186(5A):44S-54S; discussion 61S-4S.
9. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Phys 2002;66:1655-62.
10. Wu S, Armstrong DG. Risk assessment of the diabetic foot and wound. Int Wound J 2005;2(1):17-24.
11. Edmonds ME, Foster AV. Diabetic foot ulcers. BMJ 2006;332:407-10.
12. M.C. Robson, Exogenous growth factor application effect on human wound healing, Progress in Dermatology 30 (1996) 1-7.
13. Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol2003; 139:510 -16.
14. Kazemi-Khoo N. Successful treatment of diabetic foot ulcers with low-level laser therapy. The Foot, Volume 16, Issue 4, Pages 184-187.
15. Chana CM, Chana YW, Laub CH, Laub TW, Laub KM, Lamb FC, Chec CT, Leung PC, Funga KP, Laue CBS, Hoa YY. Influence of an anti-diabetic foot ulcer formula and its component herbs on tissue and systemic glucose homeostasis. Journal of Ethnopharmacology 109 (2007) 10-20.
16. Shojaie Fard, M. Esmaelzadeh, B. Larijani (2007). Assessment and treatment of diabetic foot ulcer International Journal of Clinical Practice 61 (11), 1931-1938.
17. Larijani B, Hasani Ranjbar S. Overview of diabetic foot; novel treatments in diabetic foot ulcer. DARU 2008; 16(suppl. 1): 1-6.
18. Abdollahi M, Farzamfar B, Salary P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Rodent acute and sub-chronic toxicity evaluation of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing. DARU 2008; 16(suppl. 1): 7-14.
19. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky Y.A, Farhadi M. Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. DARU 2008; 16(suppl. 1): 15-19.
20. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salary P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™). DARU 2008; 16(suppl. 1): 20-25.
21. Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™) in patients with diabetic foot ulcer: A Phase I clinical trial. DARU 2008; 16(suppl. 1): 26-30.
22. Masoompour SM, Bagheri MH, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer : A phase 2 clinical study. DARU 2008; 16(suppl. 1): 30-34.
23. Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K, Heidarpour R, Mohajeri Tehrani MR, Kamali K, Farhadi M, Gharibdoust F, Madani SH. Effects of Intravenous Semelil (ANGIPARSTM) on Diabetic Foot Ulcers Healing: A Multicenter Clinical Trial. DARU 2008; 16(suppl. 1): 35-40.
24. Unger RF, Foster DW. Diabetes mellitus. In: Williams RH, Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia (PA): WB Saunders Company; 1992. p. 1255-1333.
25. Goodson WH, Hunt TK. Studies of wound healing in experimental diabetes mellitus. J Surg Res. 1977;22(3):221-27.
26. Potemkin V, Aksenov A, Koltsova E. Endocrinology. 1st ed. Moscow (Russia): Mir Publisher; 1989. p. 221-34.
27. Richardson G . Neurogenic disorders. In: Canale ST, Campbell WC, editors. Campbell's operative orthopedics. 9th ed. St. Louis (MO): Mosby Publishing Company; 1998. p. 1813-17.
28. Akbari A, Moodi H, Ghiasi F, Mahmoudzadeh Sagheb H, Rashidi H. Effects of vacuum-compression therapy on healing of diabetic foot ulcers: Randomized controlled trial. Journal of Rehabilitation Research & Development. Volume 44 Number 5 2007 Pages 631-636.
29. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care. 1998;21(12):2161-77.
30. Foster DW. Diabetes mellitus. In: Harrison TR, Fauci AS, editors. Harrison's principles of internal medicine. 13th ed. New York (NY): McGraw Hill Company; 1998. p. 2060-81.
31. Cecil RL, Goldman L, Bennett JC. Cecil textbook of medicine. 20th ed. Philadelphia (PA): WB Saunders Company; 2000. p. 1266-68.
32. Purandare H, Supe A. Immunomodulatory role of tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: A prospective randomized controlled study. Indian J Med Sci 2007;61:347-55.
33. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003; 90: 133-46.
34. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21:71-8.
35. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor- BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21:822-7.
36. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-27.
37. D.J. Margolis, J. Kantor, J. Santanna, B.L. Strom and J.A. Berlin, Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers, Diabetes Care 24 (2001), pp. 483-488.
38. Wieman TJ, Smiell JM, Yachin S. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998; 21: 822-827.
39. V. Krishna Mohan. Recombinant human epidermal growth factor (REGEN-DTM 150): Effect on healing of diabetic foot ulcers. Diabetes Research and Clinical Practice 78 (2007) 405-411.
40. Fernández-Montequín J, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA. Intralesional injections of Citoprot-P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. International Wound Journal, Volume 4, Number 4, December 2007 , pp. 333-343.
41. S.K. Han, K.J. Choi and W.K. Kim, Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers a pilot study, Plast Reconstr Surg 114 (2004), pp. 1783-1789.
42. Conrad C, Huss R. Adult stem cell lines in regenerative medicine and reconstructive surgery. J Surg Res 2005; 124: 201-08.
43. Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol. 2003;196: 245-250.
44. Badiavas EV, Ford D, Liu P, Kouttab N, Morgan J, Richards A, Maizel A. Long-term bone marrow culture and its clinical potential in chronic wound healing. Wound Repair and Regeneration. 2007; 15: 856-865.
45. Cha J, Falanga V. Stem cells in cutaneous wound healing. Clinics in Dermatology (2007) 25, 73-78.
46. Kawamura, A, Horie, T, Tsuda, I, Ikeda, A, Egawa, H, Imamura, E, Iida, J, Sakata, H, Tamaki, T, Kukita, K, Meguro, J, Yonekawa, M, Kasai, K (2005) "Prevention of limb amputation in patients with limb ulcers by autologous peripheral blood mononuclear cells implantation" Therap Apheresis Dial 9: 59-63.
47. V Falanga, Wound healing and its impairment in the diabetic foot, Lancet 366 (2005), pp. 1736-1743.